Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (**Original**) A combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof.

2. (**Original**) A combination according to claim 1 wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.

3. (**Currently Amended**) A combination according to claim 1 ~~or claim 2~~ wherein the CDK inhibitor is selected from rosovitine, purvalanol A, purvalanol B and olomoucine.

4. (**Currently Amended**) A combination according to ~~any preceding~~ claim 1 wherein the CDK inhibitor is roscovitine.

5. (**Currently Amended**) A combination according to ~~any preceding~~ claim 1 wherein the metabolite is 1-(2-C-Cyano-2-deoxy-β-D-arabino-pentafuranosyl)-cytosine.

6. (**Currently Amended**) A pharmaceutical composition comprising a combination according to ~~any preceding~~ claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

7. (**Currently Amended**) Use of a combination according to ~~any one of~~ claims 1 ~~to 5~~ in the preparation of a medicament for the treatment of a proliferative disorder.

8. (**Original**) A pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy.

9. **(Original)** A pharmaceutical product according to claim 8 wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.

10. **(Currently Amended)** A pharmaceutical product according to claim 8 ~~or claim 9~~ wherein the CDK inhibitor is selected from rosovitine, purvalanol A, purvalanol B and olomoucine.

11. **(Currently Amended)** A pharmaceutical product according to ~~any one of~~ claim~~s~~ 8 ~~to 10~~ wherein the CDK inhibitor is roscovitine.

12. **(Currently Amended)** A pharmaceutical product according to ~~any one of~~ claim~~s~~ 8 ~~to 11~~ in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient.

13. **(Currently Amended)** A pharmaceutical product according to ~~any one of~~ claim~~s~~ 8 ~~to 11~~ for use in the treatment of a proliferative disorder.

14. **(Original)** A pharmaceutical product according to claim 13 wherein the proliferative disorder is cancer.

15. **(Original)** A pharmaceutical product according to claim 14 wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma.

16. **(Currently Amended)** A pharmaceutical product according to ~~any one of~~ claim~~s~~ 8 ~~to 15~~ wherein the metabolite is 1-(2-C-Cyano-2-deoxy-β-D-arabino-pentafuranosyl)-cytosine.

17. **(Original)** A method of treating a proliferative disorder, said method comprising administering to a subject, simultaneously, sequentially or separately, 1-(2-C-cyano-2-

dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, and a CDK inhibitor.

18. (**Original**) A method according to claim 17 which comprises administering said CDK inhibitor to a subject prior to sequentially or separately administering 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to said subject.

19. (**Original**) A method according to claim 17 which comprises administering 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject prior to sequentially or separately administering a CDK inhibitor to said subject.

20. (**Currently Amended**) A method according to ~~any one of~~ claim~~s~~ 17 ~~to 20~~ wherein the CDK inhibitor is an inhibitor of CDK2 or CDK4.

21. (**Original**) A method according to claim 20 wherein the CDK inhibitor is selected from rosovitine, purvalanol A, purvalanol B and olomoucine.

22. (**Original**) A method according to claim 21 wherein the CDK inhibitor is roscovitine.

23. (**Currently Amended**) A method according to ~~any one of~~ claim~~s~~ 17 ~~to 22~~ wherein the CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a therapeutically effective amount with respect to the individual components.

24. (**Currently Amended**) A method according to ~~any one of~~ claim~~s~~ 17 ~~to 22~~ wherein the CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a subtherapeutic amount with respect to the individual components.

25. (**Currently Amended**) A method according to ~~any one of~~ claims 17 ~~to 24~~ wherein the proliferative disorder is cancer.

26. (**Original**) A method according to claim 25 wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma.

27. (**Currently Amended**) A method according to ~~any one of~~ claims 17 ~~to 26~~ wherein the metabolite is 1-(2-C-Cyano-2-deoxy-β-D-arabino-pentafuranosyl)-cytosine.

28. (**Original**) Use of a CDK inhibitor in the preparation of a medicament for the treatment of a proliferative disorder, wherein said treatment comprises administering to a subject simultaneously, sequentially or separately 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, and a CDK inhibitor.

29. (**Original**) Use of a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof in the preparation of a medicament for treating a proliferative disorder.

30. (**Original**) Use of a CDK inhibitor in the preparation of a medicament for the treatment of a proliferative disorder, wherein said medicament is for use in combination therapy with 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof.

31. (**Original**) Use of 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, in the preparation of a medicament for the treatment of a proliferative disorder, wherein said medicament is for use in combination therapy with a CDK inhibitor.